Essentials• Accurate determination of anticoagulant plasma concentration is important in
clinical practice.• We studied the accuracy and consistency of anti‐Xa assays for …

Context The clinical introduction of new oral anticoagulants (NOACs) has stimulated the
development of tests to quantify the effects of these drugs and manage complications …

Clinicians prescribing new oral anticoagulants (OACs; dabigatran, rivaroxaban, and
apixaban) should be aware of the exclusion criteria related to bleeding risks defined in …

Essentials• The value of thrombin generation assay (TGA) in monitoring direct oral
anticoagulants (DOAC) is not well defined.• TGA parameters were measured and correlated …

Abstract Background: Rivaroxaban, a direct Xa inhibitor, is one of the new oral
antithrombotic agents for which laboratory monitoring is thought to be unnecessary in most …

We performed a review of all direct oral anticoagulant (DOAC) levels–ecarin times for
dabigatran and anti-Xa levels for rivaroxaban and apixaban–ordered at our institution with …

Background: Direct oral anticoagulants (DOACs) are prescribed for anticoagulation in
patients with atrial fibrillation and venous thromboembolic disease. Fixed doses are …

The effect of direct oral anticoagulants (DOACs) on laboratory tests dependent on the
production of their targets, factor IIa and factor Xa (FXa), is a well-known problem and can …

Background: Oral anti-Xa inhibitors have demonstrated noninferiority to vitamin K
antagonists (VKAs) for the prevention of stroke in patients with atrial fibrillation and recurrent …

Background Measurement of direct oral anticoagulants (DOACs) concentration in patient
blood is essential in special clinical circumstances. Methods We developed a fast, selective …